Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sunitinib malate and exemestane before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of sunitinib malate to see how well it works when given together with exemestane in treating postmenopausal women with breast cancer.
Epistemonikos ID: 005344cce34c318892ff2c5b5fc88649866450ff
First added on: May 05, 2024